Boston, MA 03/13/2014 (wallstreetpr) – TG Therapeutics, Inc. (NASDAQ:TGTX) is betting on a couple of formulations to fight certain types of leukemia and lymphoma. Both the compounds — TG-1101 and TGR-1202 — are under development and undergoing clinical trials.
TG Therapeutics is focused on developing cutting edge drugs such as monoclonal antibodies and delta inhibitors to fight lymphomas, leukemia, and other forms of cancer and hematological disorders.
Financial Results
As per the FY2013 results, its cash, investments and interests receivable totaled $45.4 million as of December 31, 2013. This was improved from $16.5 million as on December 31, 2012. Net loss for 4Q2013 was $5.7 million compared to $3.5 million during 4Q2012.
The increase in the net loss is on account of R&D expenses related to TG-1102 and TGR-1202.
Prospects for 2014
TG Therapeutics, Inc. (NASDAQ:TGTX) has already demonstrated clinical activity of both TG-1101 and TGR-1202. They’ve also launched two cutting edge combination clinical trials: one combining TG-1101 and ibrutinib and the other combing TG-1101 and TGR-1202. In 2014, it’s expected that the optimal single-agent dose for TGR-1202 will be determined. They also hope to present the updated single-agent data for both TG-1101 and TGR-1202. They hope to complete enrolment into both of their combination trials and start presenting medical data as they emerge with initial data coming out by June 2014.
Novel Leukemia Therapies
Development of non-chemotherapy based treatments for various leukemia and lymphomas has seen great success with blockbuster drugs like imatinib (Glivec), dasatinib (Sprycel), and nilotinib (Tasigna). All these tyrosine kinase inhibitors have proven themselves to be miracle cures for patients suffering from chronic myelogenous leukemia. While imatinib and dasatinib are first line therapies, nilotinib is a second-line therapy approved for imatinib-resistant CML.
While it’s never certain that any therapy or therapeutic combination undergoing clinical trials will necessarily end up being approved by the FDA, the prospects for TG-1101 and TGR-1202 look good so far. If they turn out to be successes, patients suffering from hematological malignancies will benefit a great deal and TG Therapeutics, Inc. (NASDAQ:TGTX) will be able to start recovering all its research and clinical trial expenses.
